Audio Recap: EASL 2022
Key Viral Hepatitis Studies Influencing My Practice Following EASL 2022—Audio Recap

Released: July 06, 2022

Expiration: July 05, 2023

Stefan Zeuzem
Stefan Zeuzem, MD

Activity

Progress
1
Course Completed

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

  • Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
  • HBV cure from the Everest Project in China
  • HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
  • HCV retreatment in patients with prior direct-acting antiviral therapy failure